Record R&D Investment In 2024, global biopharma R&D spending soared to $102 billion a 10-year high up from $71 billion in 2023 underscoring renewed investor confidence in late-stage pipelines
Table of Contents What Cagrilintide and Retatrutide Are and How They Work Approved Uses and Current Clinical Evidence in the UK How These Medicines May Affect Men Specifically Dosage, Administration, and What to Expect Side Effects, Risks, and Safety Considerations Availability on the NHS and Next Steps for Treatment Scientific References Frequently Asked Questions What Cagrilintide and Retatrutide Are and How They Work Cagrilintide is a long-acting amylin analogue that promotes satiety and slows gastric emptying, while retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite, enhance insulin secretion, and increase energy expenditure
Luo JC, Peng YL, Chen TS, et al
Stable gastric pentadecapeptide BPC 157 vascular and organoprotective effects
Whatever your goals, weve got the fuel to reach them